trial

Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS

NCTId NCT06426134
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 28 (actual)
Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Primary completion 2026-04-17
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
28 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2024-12-01
Primary completion
2026-04-17
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)Maltodextrin, Fructose, Pectin, Sodium alginate, Sodium chloride

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Lead Sponsor
Parnassia GroepCollaborator
The University of Texas at DallasCollaborator
University of AlbertaCollaborator
EnLiSenseCollaborator

Investigators

1
Karin Huizer, MD/PhDPrincipal Investigator

Sites

1 total
Amsterdam, Netherlands

Facts & assertions

4 sourced
Enrollment
28
Phase
NA
Primary Completion Date
2026-04-17
Status
COMPLETED
relationships
The graph out of here
drug
(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)
drug
Maltodextrin, Fructose, Pectin, Sodium alginate, Sodium chloride
drug
lead_sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
company
collaborator
Parnassia Groep
company
The University of Texas at Dallas
company
indication
Mania
indication
Depressive Episode
indication
Manic Episode
indication
investigator
Karin Huizer, MD/PhD
person